Baxter International (BAX) fundamentals: P/E, valuation, undervalued?
Baxter International · Health Care · ref. ETF XLV · price $25.93
In short — Baxter International trades at —× earnings (P/E), 12.7× forward, with a net margin of -9.3 % and revenue growth of +5 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Baxter International stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$25.93+6.3% over range
Aug 28, 25low $15.8 · high $28.35Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
25% recommend buying · 8 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
12.7
Forward P/E
—
PEG
2.2
Price/book (P/B)
$13.4B
Market cap
-1.84
EPS
Profitability & growth
-9.3 %
Net margin
+5 %
Revenue growth
+37 %
Earnings growth
$9.7B
Total debt
Baxter International income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $15.1B | $-2.4B | -16.1 % |
| 2023 | $14.8B | $2.7B | 17.9 % |
| 2024 | $10.6B | $-649M | -6.1 % |
| 2025 | $11.2B | $-957M | -8.5 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Baxter International's P/E and is the stock undervalued? What's a good P/E?
Baxter International's P/E is — (forward 12.7). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Baxter International profitable?
Baxter International has a net margin of -9.3 % (EPS -1.84). The company is not (yet) profitable.
Is BAX stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Baxter International? The JPI assistant answers using our backtest data.
Keep exploring Baxter International